Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Kalinsky

Showing results (1-10 of 151) with videos related to

Pageof 16
Sort By:
Expert Review of Anticancer Therapy|May 12, 2007
Novel inhibitors in the treatment of metastatic melanomaKevin Kalinsky, Frank G Haluska
Journal of Comparative Effectiveness Research|November 19, 2013
Room for improvement in breast cancer clinical trial design: taking advantage of the preoperative settingKevin Kalinsky, Dawn L Hershman
Expert Opinion on Biological Therapy|October 22, 2020
Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecanJulia E McGuinness, Kevin Kalinsky
Future Oncology (London, England)|March 21, 2019
Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancerJoyce O'Shaughnessy, Virginia Kaklamani, Kevin Kalinsky
Therapeutic Advances in Medical Oncology|March 31, 2022
Are we closer to being able to select patients with node-positive hormone receptor-positive breast cancer who can safely omit chemotherapy?Caitlin Taylor, Jane Meisel, Kevin Kalinsky
Cancers|December 11, 2022
Trop-2 as a Therapeutic Target in Breast CancerElizabeth Sakach, Ruth Sacks, Kevin Kalinsky
Seminars in Oncology|December 18, 2007
The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applicationsFrank Haluska, Trevor Pemberton, Nageatte Ibrahim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 8, 2020
Propranolol: What is BLOCKing Its Clinical Investigation in Breast Cancer?Anne H Blaes, Evidio Domingo-Musibay, Kevin Kalinsky
Breast Cancer Research and Treatment|July 2, 2021
Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2- negative breast cancerMatthew R Kearney, Julia E McGuinness, Kevin Kalinsky
British Journal of Clinical Pharmacology|May 28, 2016
AKT in cancer: new molecular insights and advances in drug developmentPrabhjot S Mundi, Jasgit Sachdev, Carolyn McCourt, et al.
Pageof 16

Showing results (1-10 of 151) with videos related to

Sort By:
Pageof 16
Expert Review of Anticancer Therapy|May 12, 2007
Novel inhibitors in the treatment of metastatic melanomaKevin Kalinsky, Frank G Haluska
Journal of Comparative Effectiveness Research|November 19, 2013
Room for improvement in breast cancer clinical trial design: taking advantage of the preoperative settingKevin Kalinsky, Dawn L Hershman
Expert Opinion on Biological Therapy|October 22, 2020
Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecanJulia E McGuinness, Kevin Kalinsky
Future Oncology (London, England)|March 21, 2019
Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancerJoyce O'Shaughnessy, Virginia Kaklamani, Kevin Kalinsky
Therapeutic Advances in Medical Oncology|March 31, 2022
Are we closer to being able to select patients with node-positive hormone receptor-positive breast cancer who can safely omit chemotherapy?Caitlin Taylor, Jane Meisel, Kevin Kalinsky
Cancers|December 11, 2022
Trop-2 as a Therapeutic Target in Breast CancerElizabeth Sakach, Ruth Sacks, Kevin Kalinsky
Seminars in Oncology|December 18, 2007
The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applicationsFrank Haluska, Trevor Pemberton, Nageatte Ibrahim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 8, 2020
Propranolol: What is BLOCKing Its Clinical Investigation in Breast Cancer?Anne H Blaes, Evidio Domingo-Musibay, Kevin Kalinsky
Breast Cancer Research and Treatment|July 2, 2021
Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2- negative breast cancerMatthew R Kearney, Julia E McGuinness, Kevin Kalinsky
British Journal of Clinical Pharmacology|May 28, 2016
AKT in cancer: new molecular insights and advances in drug developmentPrabhjot S Mundi, Jasgit Sachdev, Carolyn McCourt, et al.
Pageof 16